News

Stealth BioTherapeutics Receives Nasdaq Notifications Regarding Minimum Bid And Market Value Requirements

Stealth BioTherapeutics to Present at 2022 H.C. Wainwright BioConnect Virtual Conference

BOSTON, Jan. 4, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that Reenie McCarthy, CEO, will present at the H.C. Wainwright BioConnect Virtual Conference taking place from January 10-13, ...

Stealth BioTherapeutics Reports Positive Pre-IND Meeting for Duchenne Muscular Dystrophy

BOSTON, Dec. 20, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq:MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today reported an update on its pre-IND meeting with the FDA's Division of Cardiology and Nephrology (DCN) regarding its Duchenne muscular ...

Stealth BioTherapeutics Provides Update On Clinical Stage Rare Disease Programs

BOSTON, Dec. 13, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq:MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today reported an update on its clinical-stage rare disease programs. Duchenne muscular dystrophy (DMD). Early data from a study of elamipretide ...

Stealth BioTherapeutics Reports Third Quarter 2021 Financial Results and Recent Business Highlights

BOSTON, Nov. 11, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq:MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today reported financial results for the three months ended September 30, 2021 and announced recent business highlights. "We are excited to ...

Stealth BioTherapeutics to Report Third Quarter Financial Results on Thursday, November 11

BOSTON, Nov. 4, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that it will report third quarter 2021 financial results on Thursday, November 11, before the market opens. Management will host a ...

Stealth BioTherapeutics Receives Refusal to File Letter from the FDA

BOSTON, Oct. 20, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that it received a Refusal to File letter from the United States Food and Drug Administration (FDA) regarding Stealth's New Drug ...

Stealth BioTherapeutics Presents Positive SBT-272 Preclinical Data at 2021 Annual Northeast Amyotrophic Lateral Sclerosis (NEALS) Meeting

BOSTON, Oct. 7, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, announced today the presentation of new promising data from a study evaluating the effects of SBT-272 in a murine model of amyotrophic lateral ...

Stealth BioTherapeutics Completes a $25 Million Debt Financing with Horizon Technology Finance

BOSTON, Oct. 4, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced completion of a $25 million long-term debt facility led by Horizon Technology Finance Corporation (Nasdaq: HRZN) ("Horizon"). ...

Stealth BioTherapeutics Presents Positive Elamipretide Data in Pediatric Cardiology at International Society for Heart Research North American Section Meeting 2021

BOSTON, Sept. 28, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, announced today the presentation of positive elamipretide data showing improvements in mitochondrial respiration and heart muscle function in ...